51results about How to "Inhibition of newborns" patented technology

The invention relates to a medicine of a bispecific monoclonal antibody, and especially to a medicine of a bispecific monoclonal antibody to human vascular endothelial growth factor (VEGF/VEGF-A) and platelet-derived growth factor receptor (PDGFR) for resistance to angiogenesis of tumor. The bispecific antibody to VEGF/PDGFR beta provided in the invention is characterized in that: a monoclonal antibody to VEGF is used as the base for the antibody and a single chain antibody to PDGFR beta is connected with the terminal of FC segment of the monoclonal antibody to VEGF to form the bispecific antibody to VEGF/PDGFR beta. The bispecific antibody related to in the invention is obtained by employing technical means like gene engineering and constructing antibody segments which identify VEGF and PDGFR beta in a same antibody molecule that can be specifically bound with the two antibody segments; the effect of the bispecific antibody on inhibiting angiogenesis of tumor issue is obviously superior to that of a single antibody to VEGF; and the bispecific antibody has good activity in resisting tumors.

The invention relates to a hypoglycemic compound, its preparation method and a health food with hypoglycemic function. The compound contains the following components of: by weight, 300-600 parts of propolis, 300-600 parts of naringenin, 60-120 parts of anthocyanidin, 0.5-1.5 part of momordica polypeptide, 0.001-0.01 part of vitamin D3, 0.001-0.1 part of vitamin H, 8-15 parts of vitamin E, 0.01-0.2 part of chromium element and 1-20 parts of zinc element. The hypoglycemic compound can be prepared by directly mixing raw materials containing the above components. According to the invention, with the combination of the above components, a good synergistic effect is generated among all the components. The invention has advantages of obvious hypoglycemic function, easily-obtained raw materials, simple preparation and relatively low cost. In addition, the components of the hypoglycemic compound are all natural bioactive substances. Therefore, the compound has good security and no toxic and side-effect and is especially applicable to be used as a health food for adjunctive treatment of diabetic patients.

The invention discloses multiple transfer RNA fragments which derive from the following fragments with full-length sequences and containing 20-55 nucleotides: tRNA-val, tRNA-gly, tRNA-glu or tRNA-his, wherein the full-length sequence of tRNA-val is shown in SEQ ID NO 1, the full-length sequence of tRNA-gly is shown in SEQ ID NO 2, the full-length sequence of tRNA-glu is shown in SEQ ID NO 3, and the full-length sequence of tRNA-his is shown in SEQ ID NO 4. The transfer RNA fragments can be used for treating tumors and regulating angiogenesis.

The invention discloses an iodipin and targeted drug compound. The iodipin and targeted drug compound comprises iodipin and a targeted drug, and the targeted drug is targetingly gathered on an in-vivotumor area through the iodipin. The iodipin is adopted as an embolization agent or an area targeting agent, the targeted drug is taken into the tumor area, the targeted drug is targetingly gathered on the tumor area rather than acts on other non-tumor organ tissue, and therefore the side effects of the targeted drug are relieved. Some targeted drugs with an angiogenesis restraining function can restrain angiogenesis caused by inflammatory factor releasing caused by iodipin embolism, and therefore hyperplasia of residual tumor tissue causd by iodipin embolism embolism is restrained.

The invention relates to bispecific monoclonal antibody medicaments, and especially relates to a human vascular endothelial growth factor (VEGF/VEGF-A) resistant and human angiopoietin 2 (ANG2) resistant bispecific monoclonal antibody medicine, which is used for resisting neovascularization. The anti-VEGF/ANG2 bispecific antibody is characterized in that: a VEGF monoclonal antibody is adopted as a basis, and a second antigen binding site is replaced by an antibody segment specifically bound to ANG2.

The invention discloses an application of a blocker with integrin affinity and bonding capability and MMPs (matrix metalloproteinases) inhibiting capability, and belongs to the field of medicines. The application comprises a polypeptide I (Arg-Gly-Asp-Gly-Gly-Gly-Gly-Pro-(D-Pyr)-(D-Cys)-Bip-Arg-Gly-Glu) and a polypeptide II (Pro-(D-Pyr)-(D-Cys)-Bip-Arg-Gly-Glu-Gly-Gly-Gly-Gly-Arg-Gly-Asp), wherein the polypeptide I is modified with an integrin ligand sequence (Arg-Gly-Asp-Gly-Gly-Gly-Gly); two types of blood vessel inhibiting polypeptides with integrin affinity and bonding capability are formed. The application has the advantages that because of the targeting property of an RGD (arginine-glycin-aspartate) sequence, the polypeptides can be targeted to the new blood vessel endothelium of the RA (rheumatoid arthritis) pannus forming process, the forming of MMPs (matrix metalloproteinases) and the new blood vessel can be inhibited, and the effect of preventing or treating the blood vessel and inflammatory diseases are realized; the polypeptides can be applied to the treatment of the blood vessel and inflammatory diseases, such as arthritis, inflammation, tumors, and eye diseases.

The invention relates to a novel imidazole diphosphonie acid compound and a pharmaceutically-acceptable salt thereof. The diphosphonie acid compound disclosed by the invention, farnesylpyrophosphate synthetase is treated, and lipotropy is enhanced. The type of compound can be used for treating diseases including osteoporosis, hypercalcinemia and the like, and can be applied to cancer chemotherapy, immunotherapy and the like.

The invention discloses a polypeptide CKA18N and application of the polypeptide CKA18N or pharmaceutically acceptable salt thereof to preparation of drugs for treating and/or preventing diseases caused by angiogenesis. The polypeptide CKA18N has an amino acid sequence which has a sequence consistency of 13.18 or more when being compared with SEQ ID NO. 1. The invention furthermore discloses a pharmaceutical composition for treating diseases caused by angiogenesis; and the pharmaceutical composition comprises the polypeptide CKA18N, or the pharmaceutically acceptable salt of the polypeptide CKA18N, and a pharmaceutically acceptable carrier. Compared with the existing drugs for inhibiting angiogenesis, the polypeptide CKA18N (SEQ ID NO. 1) has the following advantages: (1) the CKA18N is as long as 18 amino acids, is easy to synthesize and low in cost; (2) the polypeptide CKA18N has a remarkable effect of inhibiting angiogenesis; and (3) the polypeptide CKA18N has relatively good solubility in water and is easily administered by injection.

The invention discloses an application of a drug composition in drug preparation for preventing or treating neovascular diseases, the drug composition is composed of six traditional Chinese medicines of Astragalus mongholicus, radix pseudostellariae, Ligustrum lucidum Ait, wolfberry fruit, leech and rheum officinale.

The invention discloses the application of a beta-2-glucoprotein-I of the natural type, the cracking type or the V structure domain deletion mutant type in preparing for a novel drug of restraining the angiogenesis. The test testifies that the natural type beta-2-glucoprotein-I (n beta₂GPI), the cracking type beta-2-glucoprotein-I (c beta₂GPI) and the V structure domain deletion mutant type beta-2-glucoprotein-I (DI-IV) can restrain the angiogenesis of the endothelial cell. The functional mechanism of the invention is that the invention influences the expression and photophosphorylation of an accepter of an endothelial cell growth factor to retain the signal conducting path of the accepter and retain the lower fifty genetic expressions and further retain the multiplication, the migration and the angiogenesis of the endothelial cell. The invention can provide novel preventing and remedying measures for clinical treatment of the diseases of the angiogenesis, such as the multiplication type retina lesion of the diabetes etc.

An antisense oligonucleotide for suppressing the synthesis of human endogenous angiogenin and its medicine composition are disclosed. The said antisense oligonucleotide can act on the mRNA of endogenous angiogenin, so suppressing its synthesis and the growth of tumor cells.

The invention discloses an anti-tumor vascular drug sustained-release embolization microsphere for malignant tumor interventional therapy, which is made of a degradable or non-degradable material and is internally loaded with an anti-tumor vascular drug for resisting tumor vessels, tumor angiogenesis and tumor angiogenesis, and the drug comprises an antibody or small molecule compound drug. The growth of original blood vessels of tumor tissues and the angiogenesis of the tumor tissues can be resisted or inhibited, so that the formation of collateral circulation of the tumor tissues is inhibited, and the growth, metastasis and relapse of tumors are inhibited. According to the present invention, the tumor blood vessel is inhibited while the tumor tissue blood supply is embolized and blocked, the tumor angiogenesis and the tumor collateral circulation formation are inhibited, and the tumor recurrence and the tumor metastasis are effectively avoided. The anti-tumor vascular drug is slowly released in a tumor area, the high drug concentration can be kept at the tumor part for a long time, the drug concentration in systemic circulation is not too high, the drug utilization rate is increased, and the side effects of the drug are relatively reduced.

The invention discloses a tumor nucleic acid vaccine based on a tissue factor, wherein a plasmid is used as a vector; the plasmid is interpolated with a DNA sequence for coding HBc, and the sequence is interpolated with a DNA sequence for coding a human-source TF target epitope polypeptide; sequence of the human-source TF target epitope polypeptide is represented in SEQ ID NO: 1, and the polypeptide is amino acid at position 74-94 of human-source TF; and an ISS sequence is included in a non-coding region of the plasmid vector. Furthermore, the invention discloses a preparation method and an application of the tumor nucleic acid vaccine. The tumor nucleic acid vaccine, through genetic engineering means, presents a sequence selected from TF and including an epitope target point onto a reconstructed hepatitis B core antigen to construct an antigen epitope nucleic acid vaccine; the antigen epitope nucleic acid vaccine is applied to a body through intramuscular injection, so as to promote expression of polypeptide including a TF target epitope, and to stimulate active immunity of the body, thus preventing and treating tumors.

The invention relates to a traditional Chinese medicine composition for improving tumor microenvironment. The traditional Chinese medicine composition mainly comprises the following components in parts by weight: lucid ganoderma, astragalus membranaceus, rabdosia rubescens, radix paeoniae rubra and medlar. The invention further provides a preparation prepared from the traditional Chinese medicine composition and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is capable of effectively suppressing the proliferation of tumor cells and promoting the death of the tumor cells, is high in suppression efficiency and free and toxic and side effects, and has good functions in improving the symptoms, controlling the tumor expansion, improving the living quality of the patients and prolonging the lifetime of the patients.

The invention relates to a flavonoid derivative with a ROCK kinase inhibiting effect, belongs to the technical field of organic synthetic medicines, and solves the technical problems that the existingglaucoma treating medicines are poor in effect, especially effective therapeutic medicines for treating glaucoma with normal intraocular pressure lack, and medicines for treating diabetic retinopathy, such as conbercept and ranibizumab, can only be applied to the later stage of a disease, are ineffective for the early stage of the disease and destroy the protective effect of VEGF on a normal retinal tissue after long-term use. A technical scheme for solving the problems is achieved by providing a compound shown as a formula I. Experimental results show that the compound has the significant ROCK kinase inhibiting effect, can effectively reduce the intraocular pressure, protect retinal ganglion cells, reduce the retinal reactive oxygen level and inhibit retinal angiogenesis, and provides anovel medication choice for clinical treatment of the glaucoma and the diabetic retinopathy.

The invention provides a pharmaceutical composition of a cortex fraxini extract and borneol as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition comprises 3.6-116 parts by weight of the cortex fraxini extract and 1 part by weight of borneol. The cortex fraxini extract mainly takes cortex fraxini total coumarin as an active ingredient, and the cortex fraxini total coumarin comprises aesculin, aesculetin, fraxin and fraxetin; the content of cortex fraxini total coumarin in the cortex fraxini extract is 75-85 wt% or above, the sum of the contents of aesculin, aesculetin, fraxin and fraxetin in the cortex fraxini extract is 55-65 wt% or above, and the content ratio of aesculin to aesculetin to fraxetin is (30.0-40.0): (2.0-4.0): (20.0-30.0): 1. The cortex fraxini extract is prepared by taking traditional Chinese medicine cortex fraxini decoction pieces or a cortex fraxini medicinal material as a raw material and adopting a combined process of alcohol extraction, macroporous resin column purification and the like. The composition disclosed by the invention can be used for remarkably inhibiting the formation of newborn lymphatic vessels in corneas and has a relatively good treatment effect on diseases such as corneal injury.

The invention relates to a medicinal composition for inhibiting angiogenesis and application thereof. The medicinal composition comprises any one composition of 2-methoxy-6-methyl-P-benzoquinone(2-methoxy-6-methyl-p-benzoquinone), 2,3-dimethoxy-5-methyl-P-benzoquinone(2,3-dimethoxy-5-methyl-p-benzoquinone) or 2-hydroxy-5-methoxy-3-methyl-P-benzoquinone(2-hydroxy-5-methoxy-3-methyl-p-benzoquinone) and appropriate pharmaceutically acceptable excipients or supporting agents; and the medicinal composition is used for inhibiting the angiogenesis and further treats or prevents angiogenesis-related diseases.

To provide a therapeutic agent for endometriosis and adenomyosis. IL-33 was identified as an exacerbating factor in endometriosis and adenomyosis, and an IL-33 antagonist, which is capable of inhibiting the function of IL-33, was found to be useful for treating, preventing or alleviating endometriosis and uterine adenomyosis.

The invention relates to a prescription with functions of reducing toxicity, enhancing efficacy and inhibiting tumors, and application of the prescription. The prescription comprises radix pseudostellariae, leech, semen arecae, agarwood, rhizoma belamcandae, radix bupleuri, flos chrysanthemi indici, herba scutellariae barbatae, Japanese climbing fern spore, earthworm, rhizoma amorphophalli, radixpulsatillae chinensis, herba lysimachiae, squama manitis, galla chinensis, fructus rubi, rhizoma polygonati odorati, rhizoma paridis, scorpion, calculus bovis factitius, cornu saigae tatariace powder,fructus amomi, raw pollen typhae, herba taraxaci, poria cocos, cortex moutan, radix rehmanniae and turtle shell. The prescription can strengthen the healthy qi of a human body, inhibit the angiogenesis around cancers, dredge the passage so as to enable cancer toxins to be discharged out of the human body, and promote the cancer toxins to induce yin heat into qi phase so as to enable the cancer toxins to be smoothly discharged by relieving bowels.

The invention discloses application of a prostaglandin E2 receptor targeting drug in treatment of diabetic retinopathy. The level of PGE2 in the vitreous fluid of a diabetic patient rises abnormally,and PGE2 needs to play a role through an EPR receptor. Therefore, when an EP4R inhibitor (AH23848) is injected into the vitreous cavity for treatment, the EP4R inhibitor inhibits the expression of anEP4R receptor, so that the PGE2 effect is inhibited, the expression of NLPR3 and IL-1 beta mRNA levels in RMECs is reduced, the damage of retinal microvascular endothelial cells in DR is reduced, andthe effect of treating proliferative diabetic retinopathy is achieved. Through detection, analysis and summarization of the inventor, the inventor analyzes and determines the pathogenesis of DR and determines that the development of DR is mediated by various inflammatory factors, fibrosis factors and angiogenesis promoting factors, so that based on the treatment target of the targeted prostaglandin E2 receptor, the drug for effectively treating DR is screened and the use method of the drug is provided.